Drug Profile
CDX 1135
Alternative Names: BRL 55730; CDX-1135; sCR1; Soluble complement receptor 1; Soluble complement receptor type 1; Soluble CR1; TP 10HD; TP10; YM 203Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Developer Celldex Therapeutics Inc
- Class Anti-ischaemics; Recombinant proteins
- Mechanism of Action Complement system protein inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Adult respiratory distress syndrome; Allotransplant rejection; Disseminated intravascular coagulation; Lung transplant rejection; Membranoproliferative glomerulonephritis; Multiple sclerosis; Reperfusion injury; Rheumatoid arthritis; Systemic lupus erythematosus; Xenotransplant rejection
Most Recent Events
- 15 Apr 2014 Discontinued - Phase-I for Membranoproliferative glomerulonephritis in USA (IV)
- 15 Apr 2014 Discontinued - Phase-II for Allotransplant rejection in USA (Parenteral)
- 05 Mar 2014 Celldex Therapeutics terminates enrolment in a phase I trial in Membranoproliferative glomerulonephritis (early-stage disease, in children, adolescents and adults) in USA (NCT01791686)